Alan M. Hanash MD PhD – MSK Bone Marrow Transplant Specialist & Cellular Therapist is a transplant surgeon based in New York, New York. Specializing in bone marrow transplantation and cellular therapy, the practice is situated at 1275 York Avenue in the 10065 postal area. The clinic serves patients requiring advanced surgical care related to hematologic malignancies and other conditions necessitating bone marrow transplantation. With a focus on precision and individualized treatment plans, the practice addresses complex cases within the specialized field of transplant surgery.
The transplant surgeon is involved in a range of procedures that include bone marrow and stem cell transplants, which are critical for patients with cancers such as leukemia, lymphoma, and multiple myeloma. This specialist’s expertise extends into cellular therapy, an area that involves the use of living cells to treat disease, often working alongside oncologists and other healthcare professionals to develop comprehensive treatment strategies. These treatments often require coordination of care before, during, and after the transplant process to ensure optimal patient outcomes.
Located in one of New York’s leading medical centers, the practice benefits from access to cutting-edge research and innovative therapeutic techniques in the field of transplant surgery. The combination of surgical skill and cellular therapy knowledge allows the specialist to provide care that integrates both established and emerging treatment modalities. Patients in the New York area seeking bone marrow transplantation and related therapies can find a resource committed to addressing the complexities of their conditions with a multidisciplinary approach.
The office can be reached by phone at 347-798-9272 for appointments and consultations. Serving the New York community, this transplant surgeon is dedicated to advancing patient care in the fields of bone marrow transplantation and cellular therapy, contributing to the broader efforts to improve survival and quality of life for patients with serious hematologic disorders.
